STAT

OCTOBER 28, 2024

A person from Iowa who recently returned to the United States from West Africa has died after contracting Lassa fever, a virus that can cause Ebola-like illness in some patients. State health officials reported the case on Monday. “I want to assure Iowans that the risk of transmission is incredibly low in our state. We continue to investigate and monitor this situation and are implementing the necessary public health protocols,” Robert Kruse, state medical director of the Iowa Depa

145

145

Drug Topics

OCTOBER 28, 2024

Industry experts gathered to discuss pharmacy benefit managers, their current grasp on the drug supply chain, and how it all impacts independent pharmacies.

Independent Pharmacies 131

Independent Pharmacies 131

STAT

OCTOBER 28, 2024

A charter company working for Charles River Laboratories, one of the largest U.S. clinical research organizations, was recently fined by Canadian authorities for improperly shipping long-tailed macaques into the country, and the flights have now prompted a probe by officials who oversee an international treaty governing endangered species. Earlier this month, the Canadian Transportation Agency fined SkyTaxi 7,500 Canadian dollars (roughly U.S. $5,400) for lacking permits to transport the primate

124

124

Pharmacy Times

OCTOBER 28, 2024

Champions for Vaccine Education, Equity, and Progress reported that the majority of pharmacists believe that it is important to prioritize vaccine development and distribution.

Immunization 118

Immunization Vaccines 118

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Fierce Healthcare

OCTOBER 28, 2024

Employers are concerned that rising healthcare costs could force them to rethink salary or wage increases, according to a new study. | Employers are concerned that rising healthcare costs could force them to rethink salary or wage increases, according to a new study.

117

117

STAT

OCTOBER 28, 2024

Promising results from a new digital therapy could help tackle one of psychiatry’s most intractable problems — hearing voices. Auditory verbal hallucinations are one of the hallmarks of psychosis, particularly in people with schizophrenia, which affects 24 million people globally. These voices often bully or abuse the voice hearer, commenting incessantly on the person’s thoughts and behavior or even urging them to harm themself.

109

109

STAT

OCTOBER 28, 2024

In a boost for clinical trial transparency, the Declaration of Helsinki was updated so that medical researchers are now responsible not only for making study results public, but also for doing so in a timely manner. Specifically, medical researchers are now told they “have a duty to make publicly available the results of their research on human participants and are accountable for the timeliness, completeness, and accuracy of their reports.

108

108

Drug Topics

OCTOBER 28, 2024

A conversation with Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic.

Mayo Clinic 98

Mayo Clinic 98

STAT

OCTOBER 28, 2024

If one can point to anything good about the H5N1 bird flu outbreak in dairy cattle — to be honest, there’s nothing good about this situation — it’s the timing. Transmission of the virus through U.S. dairy herds took off when last winter’s flu season was effectively over, making the job of looking for people infected with H5N1 an easier task in theory, though there have been plenty of human hurdles impeding those efforts.

98

98

Drug Topics

OCTOBER 28, 2024

A conversation with Sean Jeffery, PharmD, BCGP, FASCP, AGSF, director of pharmacy at Hartford HealthCare Integrated Care Partners and professor of pharmacy practice at the University of Connecticut.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 28, 2024

A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity. This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population.

Chemotherapy 86

Chemotherapy Labelling 86

Drug Topics

OCTOBER 28, 2024

Don’t miss out on the latest pharmacy insights in the Drug Topics September/October issue.

98

98

STAT

OCTOBER 28, 2024

American life expectancy is falling further behind that of other wealthy countries. Many factors account for this trend, but our increasing consumption of ultra-processed food plays a major role in early and preventable deaths. U.S. agriculture subsidies encourage the production of commodity crops like corn and soybeans, which are mostly made into processed foods or used for animal feed and biofuel production.

84

84

Fierce Healthcare

OCTOBER 28, 2024

Leaders at UnitedHealth Group and Amedisys are set to meet with the Department of Justice this week in hopes of avoiding a potential attempt to block their $3.3 billion merger deal, according to me | Leaders at UnitedHealth Group and Amedisys are set to meet with the Department of Justice this week in hopes of avoiding a potential attempt to block their $3.3 billion merger deal, according to media reports.

84

84

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

OCTOBER 28, 2024

Apple wins in patent infringement lawsuit with wearable maker Masimo, but fails to get the injunction on sales that it sought

95

95

Fierce Healthcare

OCTOBER 28, 2024

As President Joe Biden prepares to leave office at the end of this year, he is taking final steps to push one of his signature domestic priorities to accelerate the fight against cancer. | As President Joe Biden prepares to leave office at the end of this year, he is taking final steps to push one of his signature domestic priorities to accelerate the fight against cancer.

82

82

Drug Topics

OCTOBER 28, 2024

Melody Hartzler, PharmD, discusses common metabolic roadblocks to weight loss and what tools pharmacy teams can use to identify and address them.

98

98

Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.

76

76

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

OCTOBER 28, 2024

The authors note that exercise beyond 3 times per week was not associated with a lower risk of asthma, and more research is needed to confirm this finding.

73

73

Fierce Pharma

OCTOBER 28, 2024

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.&nb | While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

72

72

STAT

OCTOBER 28, 2024

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine.  Sign up  to get it in your inbox every Monday. What a difference a week makes Heading into last week, things were looking downright bleak for the country’s biggest health insurers. Stocks had tanked on the news that Elevance was spending more than expected on care for its Medicaid members.

Insurance 61

Insurance Hospitals 61

Pharmacy Times

OCTOBER 28, 2024

Pharmacists play a key role when it comes to medication substitution, especially for interchangeable biosimilars where allowed by state law.

73

73

Drug Topics

OCTOBER 28, 2024

With nearly 7 million women living in a health care desert, pharmacists can provide crucial reproductive care services.

98

98

pharmaphorum

OCTOBER 28, 2024

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies for the disorder.Data reported at the Kidney Week 2024 congress in San Diego showed that felzartamab was able to achieve "substantial" reductions in proteinuria and stabilised kidney function in the 54-subject IGNAZ study that extended for 18 months after the last dose of the antibody.

67

67

Drug Topics

OCTOBER 28, 2024

The NCPA 2024 Annual Convention and Expo runs through October 29, 2024, in Columbus, Ohio.

112

112

Fierce Pharma

OCTOBER 28, 2024

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this yea

66

66

Fierce Healthcare

OCTOBER 28, 2024

Elevance Health plans to acquire home health company CareBridge in a deal that's reportedly worth $2.7 billion. | Elevance Health plans to acquire home health company CareBridge, a deal that's reportedly worth $2.7 billion.

60

60

STAT

OCTOBER 28, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online calls, and meetings has resumed. But what can you do? The world, such as it is, continues to spin, however wobbly it may feel. So to cope, yes, we are firing up the trusty coffee kettle in brewing another cup of stimulation.

Labelling 56

Labelling Chemotherapy 56

Pharmacy Times

OCTOBER 28, 2024

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

FDA 81

FDA 81

STAT

OCTOBER 28, 2024

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Hello! Today we take note of the antagonism between gene-editing players Prime Medicine and Tessera Therapeutics, consider the issue of whether the label should be updated on a Merck drug, and more.

Labelling 56

Labelling 56

Drug Topics

OCTOBER 28, 2024

Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.

Vaccines 98

Vaccines Immunization 98

Fierce Healthcare

OCTOBER 28, 2024

Universal Health Services (UHS) beat analysts' estimates for third-quarter revenue as its top line grew 11%$3.963 billion to reach $3.96 billion thanks to solid growth by its acute c | Universal Health Services beat analysts' estimates for third-quarter revenue as its top line grew 11% to reach $3.96 billion thanks to solid growth by its acute care hospitals and behavioral health care services.

Hospitals 60

Hospitals 60

European Pharmaceutical Review

OCTOBER 28, 2024

Phase III findings showed that TREMFYA ® (guselkumab) is the first IL-23 inhibitor to demonstrate results in subcutaneous induction and maintenance therapy of Crohn’s disease. New Phase III data from Johnson & Johnson has shown that the biologic could become the first IL-23 treatment to offer both a subcutaneous and intravenous induction regimen for the autoimmune condition.

59

59